13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil

Conference Reports for NATAP


13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil

	Incident Anal Cancer Diagnosed During the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study: a collective case review - (08/13/26) Changing profiling of obesity under the new definition and its adverse complications with chronic conditions with HIV - (08/13/26) New ARTs, Treatment Incidence and outcomes of AIDS-defining illnesses after dolutegravir/lamivudine initiation in advanced HIV in the DOLCE study - (08/08/26) Long-term efficacy, safety and persistence of dolutegravir/lamivudine vs bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults-results from the 144-week observational extension phase of the DYAD study - (08/08/26) The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study - (08/08/26) Real-World Experience of Lenacapavir Long-Acting in Heavily Treatment Experienced People with HIV-1: A Retrospective Cohort of a Pharmacist Injectable Service at an Academic Medical Center - (08/07/26) Community HERO Treatment Survey: Stigma and Barriers to and Facilitators of Treatment Adherence Across a Global Population of People With HIV - (08/07/26) Participants Report Positive Experiences Switching From Subcutaneous to Intravenous Lotivibart (LVB, N6LS, VH3810109) and Cabotegravir Long-Acting Injections for HIV-1 Treatment in EMBRACE Study - (08/07/26) Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintained Viral Suppression at Week 96 in the Presence of Baseline NNRTI Resistance-Associated Mutations and/or M184I/V in Proviral DNA - (08/04/26) Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor ResistanceAssociated Mutations or M184I/V in Proviral DNA - (07/10/26) Opti-DOR: 48 week data on DOR/3TC/TDF as an alternative first-line antiretroviral therapy (ART) regimen to integrase inhibitors for people with HIV and BMI>25kg/m2 in a randomised phase 3b non-inferiority study - (08/03/26) Resistance Profile of the HIV Integrase Strand Transfer Inhibitor GS-3242, a Potent Novel Long-Acting Injectable INSTI in Clinical Development - (08/01/26) Baseline and Week 48 Resistance Analyses in the Phase 3 ARTISTRY-1 Study Evaluating the Bictegravir/Lenacapavir Single-Tablet Regimen - (08/01/26) Outcomes in Treatment-Experienced People With HIV and Detectable Viremia Switching to B/F/TAF in Routine Clinical Practice: 24-Month Results From the BICSTaR Study - (08/01/26) Low Incidence of Treatment-Emergent Resistance to Bictegravir/ Emtricitabine/Tenofovir Alafenamide Under Real-World Adherence Conditions Among People With HIV in the United States, 2018-2024 - (08/01/26) Community HERO Treatment Survey: Perceptions on Ageing Across a Global Population of People With HIV - (08/01/26) Final Assessment of Real-World Virological Effectiveness of Dolutegravir versus Bictegravir Triple Regimens in HIV Patients with High Viral Load: The BicDol Study in the French Dat'AIDS Cohort (BicDol) - high resolution - (07/31/26) Baseline Demographics in the Phase 2b Registrational EXTEND 4M Trial: Evaluating a Novel Every-4-Month Cabotegravir Formulation in a Population Who Could Benefit From PrEP - (07/30/26) Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment - (07/30/26) NEW EUROPEAN, COMMUNITY CO-CREATED SURVEY REVEALS STRONG INTEREST IN LONG-ACTING HIV TREATMENT OPTIONS BUT REPORTED IN-CLINIC CONVERSATIONS LAG BEHIND - (07/30/26) CABENUVA DEMONSTRATES SUPERIORITY TO DAILY ORAL THERAPY IN ADOLESCENTS LIVING WITH HIV, AS ViiV HEALTHCARE HIGHLIGHTS NEW LONG-ACTING INJECTABLE DATA AT AIDS 2026 - (07/30/26) Comparable Virologic Effectiveness With Long-acting Cabotegravir + Rilpivirine vs. Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide in the US-based OPERA Cohort - (07/30/26) Final Assessment of Real-World Virological Effectiveness of Dolutegravir versus Bictegravir Triple Regimens in HIV Patients with High Viral Load: The BicDol Study in the French Dat'AIDS Cohort (BicDol) - high resolution - (07/30/26) Stigma-Related Challenges for People Living With HIV and Gaps in Patient Advocacy Group Responses: Perspectives From HIV Organizational Personnel - (07/30/26) Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment - (07/29/26) Efficacy and Safety of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab as an HIV-1 Treatment for Up To 104 Weeks - (07/29/26) Randomized, Active-Controlled, Phase 2b Study Evaluating Efficacy and Safety of Switch to Islatravir (ISL) 2 mg With Ulonivirine (ULO) 200 mg Once Weekly in Virologically Suppressed Adults Living With HIV-1 - (07/29/26) Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-1 Phase 3 Trial - (07/29/26) Efficacy and Safety of Single-Tablet BIC/LEN Compared With B/F/TAF in Maintaining Virologic Suppression Across Age, Sex, Race, and Geographic Region Subgroups in ARTISTRY-2 - (07/29/26) Increased Treatment Satisfaction and Maintained Health-Related Quality of Life Among People With HIV Switching to a Bictegravir/Lenacapavir Single-Tablet Regimen From Complex Regimens: Results From the Phase 3 ARTISTRY-1 Trial - (07/29/26) Efficacy and Safety of BIC/LEN Single-Tablet Regimen in Virologically Suppressed People With HIV Aged ≥ 65 Years: Week 48 Analysis of Participants in the Phase 3 Portion of ARTISTRY-1 - (07/29/26) Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results - (07/29/26) Pharmacokinetic Data Supporting the Safety and Efficacy of BIC/LEN in Phase 3 Studies - (07/29/26) Metabolic Changes at 48 Weeks in People With HIV and Virologic Suppression Switching to Single-Tablet Bictegravir/Lenacapavir From Complex Antiretroviral Regimens: Results From the Phase 3 ARTISTRY-1 Trial - (07/29/26) Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Standard-of-Care (SOC) Therapy in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-2 Phase 3 Trial - (07/29/26) Open-Label Phase 1 Study to Evaluate Relative Bioavailability and Food Effect on the Pharmacokinetics of the Fixed-Dose Combination of Doravirine/Islatravir (100 mg/0.25 mg) in Adults Without HIV - (07/28/26) Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily as Initial HIV-1 Therapy by Demographic Subgroups: Week 48 Results From a Randomized, Active-Controlled Phase 3 Study - (07/28/26) Long-Term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Children and Adolescents With HIV-1 Aged 2 to < 18 Years - (07/28/26) In VOGUE: DTG/3TC Demonstrates Non-Inferior Efficacy to BIC/FTC/TAF as First-Line Treatment - (07/28/26) Simplification to Single-Tablet Doravirine/Islatravir From Complex Antiretroviral Regimens: Subgroup Analysis From a Randomized, Open-Label, Phase 3 Clinical Study - (07/28/26) Final assessment of real-world virological effectiveness of dolutegravir versus bictegravir triple regimens among people living with HIV and high viral load: the BicDol study in the French Dat'AIDS cohort - (07/28/26) ViiV HEALTHCARE'S 2-DRUG REGIMEN DOVATO IS AS EFFECTIVE AS 3-DRUG REGIMEN BIKTARVY IN FIRST-OF-ITS-KIND HEAD-TO-HEAD STUDY IN TREATMENT-NAïVE ADULTS LIVING WITH HIV - (07/27/26) Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy - (07/24/26) Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026e - (07/24/26) Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure - (07/22/26) Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy - (07/22/26) ViiV HEALTHCARE TO PRESENT PHASE IIIB DATA COMPARING DOVATO WITH BIKTARVY IN TREATMENT-NAÏVE ADULTS; ALONGSIDE INSTI-POWERED LONG-ACTING INJECTABLE INNOVATION AT AIDS 2026 - (07/22/26) Aging, Comorbidities Incident Anal Cancer Diagnosed During the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study: a collective case review - (08/13/26) Changing profiling of obesity under the new definition and its adverse complications with chronic conditions with HIV - (08/13/26) Inhibiting glycan degradation attenuates HIV-induced inflammaging and cognitive impairment - (08/07/26) Clinical features, treatment and outcomes of late diagnosis: Co-morbidity burden and long-term prognosis - (08/06/26) Epidemiology, risk factors and prevention of late diagnosis: Linkage to care and testing strategies - (08/06/26) Immunopathogenesis of late diagnosis: Immune recovery, persistent inflammation and consequences for transmission and disease trajectory - (08/06/26) Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial - (08/06/26) Ageing with HIV at scale: Emerging cohort of older adults living with HIV in sub-Saharan Africa: 'need integrated multi-morbidity older person clinic for PWH' - (08/06/26) Brain health in people ageing with HIV - (08/06/26) The ageing adolescents: Navigating HIV care, identity development and transition to adulthood - (08/06/26) Senescence-associated degradation of intestinal a1,2-fucose, a host-intrinsic prebiotic glycan, promotes microbial dysbiosis and gut dysfunction in people with HIV - (08/06/26) Risk of HPV-related cancers remain higher among people living with HIV in the ART era: evidence from a large U.S. cohort (MWCCS) - (08/06/26) Comorbidity and Comedication Burden in People Living with HIV Stratified by Age and Sex - (08/01/26) Body weight and BMI changes associated with DTG treatment in Brazil: results from CODE, a country-wide cohort study - (07/31/26) A high burden of metabolic syndrome and metabolic conditions in the perinatally-acquired HIV population in a central London HIV clinic - (07/31/26) The body composition signature of switching to BIC/FTC/TAF or DTG/3TC over 96 weeks - (07/31/26) Subclinical coronary atherosclerosis is prevalent among people living with HIV in Peru - (07/31/26) Pericoronary fat attenuation index reflects current rather than cumulative cardiovascular disease risk factors in the Canadian HIV and aging cohort study - (07/31/26) Predictors of depressive symptoms in people with HIV: a harmonized analysis of cohorts in Thailand, Nigeria, Kenya, Uganda and Tanzania - (07/31/26) Biological and psychosocial factors in cognitive impairment among older adults with HIV: a cross-sectional evaluation from ELEA-Brasil study - (07/31/26) Do muscle quantity and muscle quality differ in their associations with strength and physical performance in ageing people with HIV? A multimodal imaging study - (07/30/26) Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium - (07/30/26) Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration - (07/30/26) Lancet Report Recommends Paradigm Shift in Care for Older Adults with HIV - (07/30/26) Aging Research Network of CCASAnet: profiles of older adults with HIV in Latin America - (07/28/26) Pharmacotherapy profile of older people living with HIV in three Brazilian cities: the role of complexity of pharmacotherapy in medication adherence: 72%polypharmacy; 9% ARV non-adherence; 21% non-adherence concomitant medications - (07/28/26) Rheumatologic and musculoskeletal disorders, disability, and HIV-related factors among people aging with HIV in Lima, Peru: a COPCORD-based cross-sectional study - (07/28/26) PreP Perceptions, Preferences, and Unmet Need for PrEP: Results from a Multi-Country Survey - (08/07/26) Challenges in early HIV detection during CAB-LA PrEP: characterization of inconclusive serological results in ImPrEP CAB Brasil - (08/06/26) Impact of doxy-PEP on sexually transmitted infections (STI) diagnoses and antibiotic use among men who have sex with men and trans women on PrEP in Brazil: a modelling study - (08/05/26) Uptake of post-exposure prophylaxis with doxycycline (doxy-PEP) and preferred access to STI testing and doxy-PEP among gay and bisexual men who have sex with men in Taiwan: 2025 HEART survey - (08/05/26) Substantial population-level reductions in syphilis and chlamydia among gay and bisexual men after introduction of doxyPEP guidance in Australia - (08/05/26) Real-world effectiveness of doxycycline post-exposure prophylaxis for STI prevention in a Southern U.S. HIV/PrEP clinic - (08/05/26) The first six months of national injectable lenacapavir PrEP prescribing and equity, United States, June-December 2025 - (07/31/26) No HIV acquisitions among women on cabotegravir long-acting injectable PrEP despite mostly short injection delays in the US OPERA Cohort - (07/31/26) High efficacy of twice-yearly subcutaneous lenacapavir for PrEP through 52 weeks of open-label extension in PURPOSE 2 - (07/31/26) Zero HIV acquisitions with twice-yearly subcutaneous lenacapavir for PrEP during 52 weeks of open-label extension in PURPOSE 1 - (07/31/26) Real-world Utilization and Adherence of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States: Updated Results From the PrEPFACTS Study Using Healthcare Administrative Claims Data - (07/30/26) Presence, Severity, Interference With Usual and Daily Life Activities and Bothersomeness of Injection Site Reactions With Cabotegravir vs Lenacapavir: Insights From Participant Reported Outcomes in the CLARITY Study - (07/30/26) Real-world Experience Using Cabotegravir Long-Acting for HIV-1 Pre-exposure Prophylaxis in the United States From Cross-sectional Surveys and Retrospective Chart Reviews: Results From the CAPTIVATE Study - (07/30/26) Participant and Provider Experiences With Long-Acting Cabotegravir vs Lenacapavir Injections: Results From the CLARITY Study - (07/30/26) Modeling Strategies to Maximize PrEP Impact in the United States With Twice-Yearly Lenacapavir - (07/29/26) Favorable Tolerability of Lenacapavir for PrEP Administered at Participant-Chosen Anatomic Sites in PURPOSE 1 and PURPOSE 2 - (07/29/26) PURPOSE 2: Endorsement and Anticipated Challenges to Adopting Twice-Yearly Lenacapavir for HIV Pre-exposure Prophylaxis (PrEP) Among Cisgender Men Who Have Sex With Men (MSM): Qualitative Insights from the PURPOSE 2 Trial - (07/29/26) PURPOSE: Experiences with Twice-Yearly Lenacapavir for PrEP in the PURPOSE 1 pen-Label Expension Phase - (07/29/26) Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development - (07/24/26) Liver Disease, Hepatitis Lean steatotic liver disease (SLD) in people living with HIV is associated with preserved cardiometabolic profiles but comparable liver disease severity - (08/02/26) Liver transplantation in people with HIV: long-term survival, rejection trends, HCC recurrence, and metabolic outcomes - (08/02/26) Evaluation of hepatitis B virus epidemiology and impact of select demographic factors on seroprevalence within an urban clinic in the US - (08/02/26) The SAFE (steatosis-associated fibrosis estimator) score predicts incidence of advanced liver fibrosis in people living with HIV: a prospective analysis from the PROSPEC-HIV cohort - (08/02/26) Viral Suppression, Cure Immunological Comparison of Viral Control in the RIO Trial Versus HIV Elite Controllers - (08/09/26) CD4 downregulation protects HIV-1-infected cells from antibody-dependent cellular phagocytosis mediated by plasma from people with HIV-1 - (08/08/26) HIV viral control after bNAb "wash-out" - preliminary results from the RIO trial - (08/06/26) Sustained HIV-1 remission following CCR5 delta32/delta32 allogeneic hematopoietic stem cell transplantation: the Kansas City patient - (08/05/26) Evidence of HIV-1 cure following CCR5?32/?32 allogeneic HSCT under complex virological conditions - (08/05/26) IL-15 superagonist N-803, with or without bNAbs, induces temporary reduction and transcriptional activation of the intact HIV reservoir - (08/05/26)